Literature DB >> 29703716

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Claire M Lucas1,2, Laura J Scott1, Natasha Carmell1, Alison K Holcroft1, Robert K Hills3, Alan K Burnett3, Richard E Clark1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29703716      PMCID： PMC5941996          DOI： 10.1182/bloodadvances.2017013615

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  23 in total

1.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Richard E Clark
Journal:  Haematologica       Date:  2015-02-06       Impact factor: 9.941

3.  CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.

Authors:  M Niemelä; O Kauko; H Sihto; J-P Mpindi; D Nicorici; P Pernilä; O-P Kallioniemi; H Joensuu; S Hautaniemi; J Westermarck
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

4.  Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

Authors:  K Nakatani; D A Thompson; A Barthel; H Sakaue; W Liu; R J Weigel; R A Roth
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

5.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

6.  SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.

Authors:  Ion Cristóbal; Francisco J Blanco; Laura Garcia-Orti; Nerea Marcotegui; Carmen Vicente; José Rifon; Francisco J Novo; Eva Bandres; María J Calasanz; Carmelo Bernabeu; María D Odero
Journal:  Blood       Date:  2009-11-16       Impact factor: 22.113

7.  MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

Authors:  Anchit Khanna; Camilla Böckelman; Annabrita Hemmes; Melissa R Junttila; Jan-Patrik Wiksten; Mikael Lundin; Siina Junnila; Daniel J Murphy; Gerard I Evan; Caj Haglund; Jukka Westermarck; Ari Ristimäki
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

8.  Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Mhairi Copland; Joseph R Slupsky; Richard E Clark
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

9.  Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

Authors:  Anni Laine; Harri Sihto; Christophe Come; Mathias T Rosenfeldt; Aleksandra Zwolinska; Minna Niemelä; Anchit Khanna; Edward K Chan; Veli-Matti Kähäri; Pirkko-Liisa Kellokumpu-Lehtinen; Owen J Sansom; Gerard I Evan; Melissa R Junttila; Kevin M Ryan; Jean-Christophe Marine; Heikki Joensuu; Jukka Westermarck
Journal:  Cancer Discov       Date:  2013-01-10       Impact factor: 39.397

10.  High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.

Authors:  C M Lucas; M Milani; M Butterworth; N Carmell; L J Scott; R E Clark; G M Cohen; S Varadarajan
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528
View more
  7 in total

1.  PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.

Authors:  Mario Scarpa; Prerna Singh; Christopher M Bailey; Jonelle K Lee; Shivani Kapoor; Rena G Lapidus; Sandrine Niyongere; Jaya Sangodkar; Yin Wang; Danilo Perrotti; Goutham Narla; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2021-02-10       Impact factor: 6.009

2.  FAM122A promotes acute myeloid leukemia cell growth through inhibiting PP2A activity and sustaining MYC expression.

Authors:  Man-Hua Liu; Jing Chen; Yun-Sheng Yang; Yin-Qi Wang; Guo-Qiang Chen; Yu Zhang; Ying Huang
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

3.  Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.

Authors:  Richard E Clark; Ammar A Basabrain; Gemma M Austin; Alison K Holcroft; Sandra Loaiza; Jane F Apperley; Christopher Law; Laura Scott; Alexandra D Parry; Laura Bonnett; Claire M Lucas
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

4.  Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation.

Authors:  Nhu Nguyen; Kristbjorn O Gudmundsson; Anthony R Soltis; Kevin Oakley; Kartik R Roy; Yufen Han; Carmelo Gurnari; Jaroslaw P Maciejewski; Gary Crouch; Patricia Ernst; Clifton L Dalgard; Yang Du
Journal:  iScience       Date:  2021-12-25

5.  Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia.

Authors:  Eleonora Mäkelä; Eliisa Löyttyniemi; Urpu Salmenniemi; Otto Kauko; Taru Varila; Veli Kairisto; Maija Itälä-Remes; Jukka Westermarck
Journal:  Cancers (Basel)       Date:  2019-11-11       Impact factor: 6.639

Review 6.  Redox inhibition of protein phosphatase PP2A: Potential implications in oncogenesis and its progression.

Authors:  Deepika Raman; Shazib Pervaiz
Journal:  Redox Biol       Date:  2019-01-14       Impact factor: 11.799

Review 7.  The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias.

Authors:  Raffaella Pippa; Maria D Odero
Journal:  Cells       Date:  2020-02-26       Impact factor: 6.600
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.